This Notice of Funding Opportunity (NOFO) issued by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) invites applications to participate as Core Clinical Centers and Consortia (CCCs) in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
Core Clinical Centers and Consortia are expected to support and conduct multi-site trials to compare novel treatment approaches and management strategies for children and adults undergoing hematopoietic stem cell transplantation (HCT) for non-malignant and malignant blood diseases, either alone or in combination with novel adoptive cell-based therapies. The companion NOFO, RFA-HL-24-011, invites applications to participate as the Data Coordinating Center (DCC) for the BMT CTN. The CCCs will collaborate with the DCC, the NHLBI, the NCI, and other stakeholders to facilitate trials for HCT and cell therapies for blood diseases. The overall goals are to identify and address gaps in HCT and adoptive cell therapy outcomes for blood diseases; provide a platform to train emerging clinical trial investigators; build a biorepository for future research that includes specimens linked to clinical data and outcomes from patients with non-malignant blood diseases; rapidly disseminate study results to improve the scientific basis of HCT and adoptive cell therapies; and ultimately improve the life and quality of life for patients who receive HCT or adoptive cell therapies. This is an open competition for new applications and/or the renewal of an existing program.